- Home
- KOD vs CADL Comparison
KOD vs CADL Comparison
Compare KOD & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- CADL
- Stock Information
- Founded
- KOD 2009
- CADL 1999
- Country
- KOD United States
- CADL United States
- Employees
- KOD N/A
- CADL N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- KOD Health Care
- CADL Health Care
- Exchange
- KOD Nasdaq
- CADL Nasdaq
- Market Cap
- KOD 186.3M
- CADL 159.1M
- IPO Year
- KOD 2018
- CADL 2021
- Fundamental
- Price
- KOD $8.72
- CADL $8.75
- Analyst Decision
- KOD Hold
- CADL Strong Buy
- Analyst Count
- KOD 5
- CADL 1
- Target Price
- KOD $6.80
- CADL $19.00
- AVG Volume (30 Days)
- KOD 484.9K
- CADL 9.7M
- Earning Date
- KOD 11-14-2024
- CADL 11-14-2024
- Dividend Yield
- KOD N/A
- CADL N/A
- EPS Growth
- KOD N/A
- CADL N/A
- EPS
- KOD N/A
- CADL N/A
- Revenue
- KOD N/A
- CADL N/A
- Revenue This Year
- KOD N/A
- CADL N/A
- Revenue Next Year
- KOD N/A
- CADL N/A
- P/E Ratio
- KOD N/A
- CADL N/A
- Revenue Growth
- KOD N/A
- CADL N/A
- 52 Week Low
- KOD $2.19
- CADL $1.08
- 52 Week High
- KOD $11.60
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- KOD 64.72
- CADL 68.05
- Support Level
- KOD $8.03
- CADL $5.90
- Resistance Level
- KOD $9.55
- CADL $7.28
- Average True Range (ATR)
- KOD 0.89
- CADL 1.61
- MACD
- KOD -0.08
- CADL 0.37
- Stochastic Oscillator
- KOD 36.51
- CADL 55.04
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.